Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Actinogen Medical ( (AU:ACW) ) just unveiled an update.
Actinogen Medical has applied to the ASX for quotation of 66.7 million new ordinary fully paid shares, expanding its listed securities under the code ACW. The issuance of these shares, some of which relate to an employee incentive scheme, increases the company’s equity base and may affect its capital structure and share liquidity for existing and new investors.
The additional quoted securities position Actinogen to potentially support ongoing corporate or operational initiatives while broadening participation in its share register. This move underscores the company’s continued reliance on public markets for funding and could influence market perceptions of its growth trajectory and financing strategy.
The most recent analyst rating on (AU:ACW) stock is a Buy with a A$0.08 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical Limited is a biotechnology company listed on the ASX, focused on developing medical therapies and operating within the life sciences sector. The company’s ordinary fully paid shares trade under the ticker ACW, reflecting its status as a publicly listed entity seeking capital from equity markets.
Average Trading Volume: 2,871,369
Technical Sentiment Signal: Sell
Current Market Cap: A$122.1M
For detailed information about ACW stock, go to TipRanks’ Stock Analysis page.